CareDx Inc. stocks have been trading up by 23.03 percent after upbeat transplant diagnostics news fueled strong investor optimism.
Key Takeaways
- Q3 2026 results from CareDx crushed expectations, with revenue of about $139M versus roughly $122M expected and GAAP EPS jumping to $0.35 from $0.03 a year ago.
- Management raised FY26 revenue guidance to $520M–$530M and boosted adjusted EBITDA targets to $90M–$100M, signaling stronger growth and margin expansion.
- Adjusted EPS of $0.70 in Q3 highlighted sharply improved profitability and operating leverage at CDNA.
- Canaccord and BTIG raised price targets to $80 and $81 and reiterated Buy ratings, backing the bullish setup around CDNA.
- Fresh AlloSure Kidney and AlloSure Plus data from ASN Kidney Week 2026 strengthened the clinical story and long‑term demand backdrop for CareDx.
Live Update At 12:32:32 EDT: On Friday, October 30, 2026 CareDx Inc. stock [NASDAQ: CDNA] is trending up by 23.03%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
CDNA has shifted from grind mode to full-on momentum. Over the past few weeks, CareDx has marched from the mid-$60s to close near $88 on 2026/10/30, with a huge range day that topped out just under $91. That kind of expansion in both price and intraday range is exactly what active traders hunt.
The earnings print explains a lot of this power. CareDx posted Q3 revenue of about $139M versus roughly $122M expected, and Q3 GAAP EPS of $0.35 versus $0.03 a year earlier. On an adjusted basis, EPS hit $0.70, showing that CDNA is not just growing, it is scaling efficiently.
Margins and balance sheet quality back up the move. A roughly 70% gross margin and very low debt (total debt to equity near 0.05, strong current and quick ratios) give CareDx room to keep pushing growth without stressing the books. With a price-to-sales near 7 and a P/E around 31, traders are clearly willing to pay up for this trajectory, but they will demand continued beats to keep CDNA elevated.
More Breaking News
- AVGO Stock Firms Up As Broadcom Shows Strong Profits And Cash
- SPCX Slides As SpaceX Faces Geopolitics, Competition, AI Risks
- TNMG Stock Pulls Back As Traders Eye Debt And Support
- WFF Stock Plunges Then Bases As Volatility Grips Chart
Intraday, the 5‑minute tape shows tight consolidations around $88 after the gap, a sign of dip buyers supporting the new range and shorts getting squeezed if they overstay.
Why Traders Are Watching CDNA Momentum
The real fuel behind this CDNA move is guidance. After Q3, CareDx raised its FY26 revenue outlook to $520M–$530M from $490M–$500M and took adjusted EBITDA guidance up to $90M–$100M from $66M–$78M. That is not a small tweak. That is management planting a flag that growth and profitability are both running ahead of plan.
For traders, guidance hikes often matter more than the quarter itself. When a name like CDNA tells the market it expects $20M–$30M more in sales and a big jump in EBITDA, models across the Street reset higher. That is the kind of shift that supports multiple expansion and brings in momentum trading desks that chase strong fundamentals.
Layer on the Q3 beat: CareDx delivered revenue of $139.4M versus about $122M expected, and adjusted EPS of $0.70. That is a sizable positive surprise. CDNA also printed a clean year-over-year step-up in GAAP EPS from $0.03 to $0.35, which shows operating leverage kicking in as its transplant and specialty oncology businesses scale.
The sell side is responding. Canaccord bumped its CDNA target to $80 from $65, and BTIG nudged its target to $81 from $74, both with Buy calls and comments about strong fundamentals and underappreciated value. For short-term traders, back-to-back target hikes provide narrative oxygen that can push a breakout further than the charts alone might suggest.
Underneath the numbers, CareDx keeps adding clinical proof. New data from ASN Kidney Week 2026 show AlloSure Kidney and AlloSure Plus can predict kidney transplant rejection and cut down on invasive biopsies, even under tough new Banff 2024 criteria. That kind of validation helps CDNA defend pricing and win share, which feeds right back into those higher revenue and EBITDA targets.
Conclusion
For active traders, CDNA is a textbook example of how strong fundamentals can light up a chart. CareDx combined a big top-line beat, a sharp jump in GAAP and adjusted EPS, and a sizable raise to FY26 revenue and EBITDA guidance. The stock’s move from the $60s to the high $80s lines up cleanly with that narrative, and the intraday tape shows solid support as CDNA digests its gap. In many ways, the move also reflects classic trading discipline: as Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.” With CDNA, the strong uptrend, elevated volume, and clear fundamental and clinical catalysts give traders multiple boxes checked on that front.
The story is not just financial. CareDx is backing its transplant-testing franchise with fresh, multinational data on AlloSure Kidney and AlloSure Plus, showing fewer biopsies and strong rejection prediction under Banff 2024 standards. That gives traders a real-world demand engine to tie to the numbers, rather than a hype-only move. Low leverage and healthy liquidity reduce balance sheet risk, which helps keep focus on growth and margins.
Still, this is not a one-way bet. A richer P/E and price-to-sales ratio mean CDNA will have to keep beating expectations to hold its premium. Any stumble in future quarters or guidance could flip momentum fast. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only about price action and catalysts — study both relentlessly.” For CDNA, those catalysts are lined up right now, and disciplined traders will watch to see if the next earnings and clinical updates keep the trend intact.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.